Zobrazeno 1 - 10
of 168
pro vyhledávání: '"Deniz, Tural"'
Autor:
Hatice Bolek, Cagatay Arslan, Mert Basaran, İrfan Cicin, Mustafa Ozguroglu, Deniz Tural, Yüksel Ürün
Publikováno v:
JCO Global Oncology, Vol , Iss 10 (2024)
PURPOSEDurable complete response rates for metastatic renal cell carcinoma (mRCC) and metastatic bladder cancer (mBC) are low despite new therapy. Palliative care focuses on life extension and quality of life (QoL), not cure. This study aims to inves
Externí odkaz:
https://doaj.org/article/cb5cd9d0b8f74576a1727fb5374b5887
Autor:
İlkay Gültürk, Gülçin Şahingöz Erdal, Gülru Birce Sönmezoz, Mesut Yılmaz, Seher Yıldız Tacar, Aykut Özmen, Deniz Tataroğlu Özyükseler, Özgecan Dulgar, İbrahim Çil, Deniz Tural
Publikováno v:
İstanbul Medical Journal, Vol 23, Iss 4, Pp 269-274 (2022)
Introduction:For metastatic prostate cancer (PC), androgen deprivation therapy (ADT) is the primary treatment option. Most patients develop resistance, after an initial response to treatment. This study aimed to evaluate real-life data of first-line
Externí odkaz:
https://doaj.org/article/4fd073773cc34e1c9b30ce4d1b0e41c1
Autor:
Kadriye Bir Yücel, Emre Yekedüz, Serdar Karakaya, Deniz Tural, İsmail Ertürk, Cihan Erol, Özlem Ercelep, Nihan Şentürk Öztaş, Çağatay Arslan, Gökhan Uçar, Ahmet Küçükarda, Özlem Nuray Sever, Saadettin Kılıçkap, Orçun Can, Satı Coşkun Yazgan, Berna Öksüzoğlu, Nuri Karadurmuş, Mehmet Ali Şendur, Yüksel Ürün
Publikováno v:
Scientific Reports, Vol 12, Iss 1, Pp 1-9 (2022)
Abstract This study aims to investigate the prognostic value of the systemic immune-inflammation index (SII)and its impact on survival in patients with metastatic renal cell carcinoma (mRCC). A total of 706patients with mRCC treated with tyrosine kin
Externí odkaz:
https://doaj.org/article/ff731989e9c14a97850334af8794a507
Publikováno v:
Namık Kemal Tıp Dergisi, Vol 10, Iss 3, Pp 228-234 (2022)
Aim:The purpose of this study was to investigate the prognostic role of pretreatment Prognostic Nutritional Index (PNI) in metastatic renal cell carcinoma (mRCC) patients given pazopanib or sunitinib as first-line targeted therapy.Materials and Metho
Externí odkaz:
https://doaj.org/article/61924a98bb904bd18229e106677ce7c3
Autor:
Cihan Erol, Emre Yekedüz, Deniz Tural, Serdar Karakaya, Nihan Şentürk Öztaş, Gökhan Uçar, Saadettin Kılıçkap, İsmail Ertürk, Özlem Nuray Sever, Çağatay Arslan, Ahmet Küçükarda, Orçun Can, Özlem Balvan, Satı Coşkun Yazgan, Mustafa Özgüroğlu, Berna Öksüzoğlu, Mehmet Ali Nahit Şendur, Yüksel Ürün
Publikováno v:
Urologia Internationalis. :1-7
Introduction: We aimed to evaluate clinical features, prognostic factors, and treatment preferences in patients with non-clear cell renal cell carcinoma (nccRCC). Methods: Patients with metastatic nccRCC were selected from the Turkish Oncology Group
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9bf0bfca5db9383fcb30bc0a60930218
https://doi.org/10.1159/000528994
https://doi.org/10.1159/000528994
Autor:
Mutlu Hizal, Burak Bilgin, Nail Paksoy, Saadettin Kılıçkap, Muhammed Mustafa Atcı, Seda Kahraman, Merve Keskinkılıç, İrem Bilgetekin, Murat Ayhan, Deniz Tural, Önder Eren, Fatma Nihan Akkoç Mustafayev, Şebnem Yaman, Ali Murat Tatlı, Ertuğrul Bayram, Yasin Kutlu, İsmail Ertürk, Erkan Özcan, Ahmet Gülmez, Mustafa Korkmaz, Baran Akagündüz, Dilek Erdem, Tuğba Akın Telli, Asude Aksoy, Necdet Üskent, Yakup İriağaç, Naziyet Köse Baytemür, Dinçer Aydın, Teoman Şakalar, Hacı Arak, Fatih Selçukbiricik, Yakup Ergün, Taner Korkmaz, Naziye Ak, Çağlar Ünal, Nadiye Akdeniz, Mehmet Alpaslan Özgün, Berna Öksüzoğlu, Bülent Yalçın, İlhan Öztop, Efnan Algın, Abdullah Sakin, Adnan Aydıner, Perran Fulden Yumuk, Mehmet Ali Nahit Şendur
Publikováno v:
Future Oncology. 18:2573-2582
Aims: In this multicenter study, the authors aimed to determine the real-life efficacy and safety of first-line alectinib. Materials & methods: This retrospective trial included advanced-stage, ALK-positive non-small-cell lung cancer patients who wer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::043d1a22a8f3e83e986a7039a57bac7a
https://doi.org/10.2217/fon-2022-0083
https://doi.org/10.2217/fon-2022-0083
Autor:
Matteo Santoni, Zin W. Myint, Thomas Büttner, Hideki Takeshita, Yohei Okada, Elaine T. Lam, Danielle Gilbert, Zsófia Küronya, Deniz Tural, Renate Pichler, Enrique Grande, Simon J. Crabb, Robert Kemp, Francesco Massari, Sarah Scagliarini, Roberto Iacovelli, Nuno Vau, Umberto Basso, Marco Maruzzo, Javier Molina-Cerrillo, Luca Galli, Aristotelis Bamias, Ugo De Giorgi, Paolo Andrea Zucali, Mimma Rizzo, Emmanuel Seront, Lazar Popovic, Orazio Caffo, Sebastiano Buti, Ravindran Kanesvaran, Jindrich Kopecky, Jakub Kucharz, Annalisa Zeppellini, Ondřej Fiala, Johannes Landmesser, Jawaher Ansari, Patrizia Giannatempo, Alessandro Rizzo, Ignacio Ortego Zabalza, Fernando Sabino M. Monteiro, Nicola Battelli, Fabio Calabrò, Camillo Porta
Publikováno v:
Cancer Immunology, Immunotherapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d073e80624dad7dc9971e9ffe0fbfa8d
https://doi.org/10.1007/s00262-023-03469-5
https://doi.org/10.1007/s00262-023-03469-5
Autor:
Deniz Tural, Cagatay Arslan, Fatih Selcukbiricik, Omer Fatih Olmez, Emre Akar, Mustafa Erman, Yüksel Ürün, Dilek Erdem, Nuri Karadurmus, Saadettin Kilickap
This 5-year analysis of real-world data confirms the durable response and long-term survival with ICTs in a broader range of patients with metastatic urothelial carcinoma. After 24 months, PFS and OS curves remained nearly flat. The safety profile wa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8485e29d30f33b7a367a23c94a9c85a7
https://hdl.handle.net/20.500.12511/11178
https://hdl.handle.net/20.500.12511/11178
Autor:
Saadettin Kilickap, Ahmet Taner Sümbül, Hasan Şenol Coşkun, Deniz Tural, Ömer Fatih Ölmez, Fatih Selcukbiricik, Mustafa Erman, Mehmet Artac
Publikováno v:
International Journal of Clinical Oncology
Background: atezolizumab (ATZ) has demonstrated antitumor activity in previous studies in patients with metastatic platinum-resistant urothelial carcinoma. However, the response rate of ATZ was modest. Therefore, finding biologic or clinical biomarke
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::984dda7abd94d637b5f5356974999c38
https://doi.org/10.1007/s10147-021-02072-x
https://doi.org/10.1007/s10147-021-02072-x
Autor:
Deniz Tural
The data involved in this project are used to answer the following research questions: what are the classes of errors that characterize invalid DOIs? Which classes of errors can be addressed through automatic processes so as to get the correct DOIs?
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c56c83ecef49ffd62ff23e46dcf051a